Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPGL008 in Non-Muscle-Invasive Bladder Cancer
NCT07445308Phase 2Not yet recruiting
- Sponsor
- 3SBio
- Start
- Mar 2026
- Primary completion
- Nov 2028
- Modality
- Biological product
01
Overview
A Phase 2 trial of SPGL008 in Non-muscle-invasive bladder cancer (NMIBC), sponsored by 3SBio. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SPGL008
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07445308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07445308.